Literature DB >> 9262371

II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1.

R J Primus1, A Thurkauf, J Xu, E Yevich, S McInerney, K Shaw, J F Tallman, D W Gallagher.   

Abstract

The dopamine D4 selective ligand, [H]NGD 94-1, was used in these studies to characterize binding sites in rat and human brain tissue by membrane binding and autoradiography techniques. Autoradiographic analysis of rat brain showed that specific [3H]NGD 94-1 binding was greatest in entorhinal cortex, lateral septal nucleus, hippocampus and the medial preoptic area of the hypothalamus. This nonstriatal distribution of [3H]NGD 94-1 binding was distinct from the autoradiographic distribution of dopamine D2 and D3 receptor subtypes. In homogenate preparations from rat brain regions, [3H]NGD 94-1 binding sites were low in density (<30.0 fmol/mg protein). The low density of D4 binding sites was corroborated by autoradiographic comparisons in which binding density for D4 receptors as measured by [3H]NGD 94-1 was only 1/7 of D2 and 1/5 of D3 receptor densities, despite corrections for differing radioligand binding characteristics. Pharmacological evaluation showed high affinity at rat [3H]NGD 94-1 binding sites for compounds with known D4 receptor affinity and little displacement by compounds with affinity for dopamine D1/D2/D3 receptor subtypes. Specific, high-affinity [3H]NGD 94-1 binding was also present in several human brain regions, including hippocampus, hypothalamus, dorsal medial thalamus, entorhinal cortex, prefrontal cortex and lateral septal nucleus. High-affinity [3H]NGD 94-1 binding was not present in any human striatal region examined. The pharmacological profile of [3H]NGD 94-1 binding sites in human brain was consistent with that previously demonstrated for cloned human D4 receptors expressed in mammalian cells. These findings suggest that specific, high-affinity [3H]NGD 94-1 binding exists in rat and human brain and that these sites reflect populations of dopamine D4 receptors with a distribution unique among dopamine receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9262371

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

Review 1.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

2.  Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors.

Authors:  Enza Lacivita; Paola De Giorgio; Irene T Lee; Sean I Rodeheaver; Bryan A Weiss; Claudia Fracasso; Silvio Caccia; Francesco Berardi; Roberto Perrone; Ming-Rong Zhang; Jun Maeda; Makoto Higuchi; Tetsuya Suhara; John A Schetz; Marcello Leopoldo
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

3.  mRNA expression of dopamine receptors in peripheral blood lymphocytes of computer game addicts.

Authors:  Nasim Vousooghi; Seyed Zeinolabedin Zarei; Mitra-Sadat Sadat-Shirazi; Fatemeh Eghbali; Mohammad Reza Zarrindast
Journal:  J Neural Transm (Vienna)       Date:  2015-05-14       Impact factor: 3.575

Review 4.  Genetics of impulse control disorders in Parkinson's disease.

Authors:  Florence Cormier; Julia Muellner; Jean-Christophe Corvol
Journal:  J Neural Transm (Vienna)       Date:  2012-12-12       Impact factor: 3.575

Review 5.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

7.  Molecular connectivity disruptions in males with major depressive disorder.

Authors:  Rajapillai Li Pillai; Mengru Zhang; Jie Yang; J John Mann; Maria A Oquendo; Ramin V Parsey; Christine DeLorenzo
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-09       Impact factor: 6.200

8.  Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

Authors:  Jorge D Brioni; Robert B Moreland; Marlon Cowart; Gin C Hsieh; Andrew O Stewart; Petter Hedlund; Diana L Donnelly-Roberts; Masaki Nakane; James J Lynch; Teodozyi Kolasa; James S Polakowski; Mark A Osinski; Kennan Marsh; Karl-Erik Andersson; James P Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-15       Impact factor: 11.205

9.  FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia.

Authors:  Frank Boeckler; Holger Russig; Weining Zhang; Stefan Löber; John Schetz; Harald Hübner; Boris Ferger; Peter Gmeiner; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

10.  Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist.

Authors:  Jinbin Xu; Suwanna Vangveravong; Shihong Li; Jinda Fan; Lynne A Jones; Jinquan Cui; Ruike Wang; Zhude Tu; Wenhua Chu; Joel S Perlmutter; Robert H Mach
Journal:  Neuroimage       Date:  2013-01-17       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.